Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Jiarui Hu,Dan Zhang,Keyue Tian,Changyu Ren,Heng Li,Congcong Lin,Xiaoli Huang,Jie Liu,Wuyu Mao,Jifa Zhang

DOI: https://doi.org/10.1016/j.ejmech.2023.115475

IF: 7.088

2023-05-12

European Journal of Medicinal Chemistry

Abstract:Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse array of cellular processes, including vesicle transport, autophagy, lysosome degradation, neurotransmission, and mitochondrial activity. Hyperactivation of LRRK2 triggers vesicle transport dysfunction, neuroinflammation, accumulation of α-synuclein, mitochondrial dysfunction, and the loss of cilia, ultimately leading to Parkinson's disease (PD). Therefore, targeting LRRK2 protein is a promising therapeutic strategy for PD. The clinical translation of LRRK2 inhibitors was historically impeded by issues surrounding tissue specificity. Recent studies have identified LRRK2 inhibitors that have no effect on peripheral tissues. Currently, there are four small-molecule LRRK2 inhibitors undergoing clinical trials. This review provides a summary of the structure and biological functions of LRRK2, along with an overview of the binding modes and structure-activity relationships (SARs) of small-molecule inhibitors targeting LRRK2. It offers valuable references for developing novel drugs targeting LRRK2.

chemistry, medicinal